secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001213900-23-050240
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix announces FDA acceptance of DefenCath NDA resubmission; PDUFA date Nov 15, 2023
--------------------------------------------------------------------------------

- FDA accepted DefenCath NDA resubmission as a complete Class 2 response with six-month review.
- PDUFA target action date set for November 15, 2023.
- DefenCath is a catheter lock solution to reduce bloodstream infections in hemodialysis patients.
- CEO Joe Todisco highlighted preparations for potential commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023050240/0001213900-23-050240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023050240/ea180659-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-050240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer